Please use this identifier to cite or link to this item: http://repo.lib.jfn.ac.lk/ujrr/handle/123456789/13226
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYadhury, S.-
dc.contributor.authorKalki, P.-
dc.contributor.authorKamshana, K.-
dc.contributor.authorDiluxcy, R.-
dc.contributor.authorNarani, A.-
dc.date.accessioned2026-11-17T03:14:55Z-
dc.date.available2026-11-17T03:14:55Z-
dc.date.issued2026-
dc.identifier.urihttp://repo.lib.jfn.ac.lk/ujrr/handle/123456789/13226-
dc.description.abstractBackground and objective Methotrexate is the anchor disease-modifying anti-rheumatic drug for rheumatoid arthritis, but elevations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) require clinical review and monitoring. This study determined the occurrence of deranged liver enzymes and associated factors among methotrexate-treated patients with rheumatoid arthritis. Methods A hospital-based descriptive cross-sectional study was conducted among 221 adults receiving methotrexate for at least six months at the Rheumatology Clinic, Teaching Hospital, Jaffna. Data were collected using an interviewer-administered questionnaire and a clinical-record extraction form. Deranged liver enzymes were defined as ALT or AST exceeding 1.5 times the upper limit of normal in any of the three most recent consecutive reports available at the time of data collection. Categorical and continuous variables were analyzed using the Chi-square/Fisher's exact test and Mann–Whitney U test, respectively, with p<0.05 indicating statistical significance. Results Deranged liver enzymes were identified in 20 participants (9.0%). Participants were predominantly female (85.5%); median age was 57 years (IQR 48–65), median weekly methotrexate dose was 10 mg (IQR 7.5–12.5), and median treatment duration was 5 years (IQR 2–7). Oral traditional medicine use was associated with deranged liver enzymes (21.7% among users versus 7.6% among non-users; p=0.042). Age, sex, alcohol use, concomitant anti-rheumatic therapy, methotrexate dose and treatment duration were not significantly associated. Conclusions Approximately one in eleven methotrexate-treated patients had deranged liver enzymes. Concomitant traditional medicine use was the only identified associated factor. Medication reconciliation and evaluation of alternative causes should accompany routine transaminase monitoring; causation cannot be inferred from this cross-sectional study.en_US
dc.language.isoenen_US
dc.publisherFaculty of Medicine University of Jaffna, Sri Lankaen_US
dc.subjectRheumatoid arthritisen_US
dc.subjectMethotrexateen_US
dc.subjectAminotransferasesen_US
dc.subjectTraditional medicineen_US
dc.subjectCross-sectional studyen_US
dc.titleOccurrence of deranged liver enzymes among patients with rheumatoid arthritis treated with methotrexateen_US
dc.typeConference paperen_US
Appears in Collections:Pharmacy

Files in This Item:
File Description SizeFormat 
2026-RCFMJ- kalki 2.pdf288.03 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.